LigaChem Biosciences리가켐바이오
141080 · KOSDAQ · ₩141080 · 리가켐바이오
₩66,200▲ ₩2,300 (3.60%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩142B | ₩126B | ₩34B | ₩33B | ₩32B |
| Cost of sales | ₩16B | ₩16B | ₩16B | ₩16B | ₩14B |
| Gross profit | ₩126B | ₩110B | ₩18B | ₩18B | ₩18B |
| Operating income | −₩106B | −₩21B | −₩81B | −₩50B | −₩28B |
| Net income | −₩92B | ₩7.8B | −₩74B | −₩45B | −₩23B |
| Net income to shareholders | −₩92B | ₩7.8B | −₩74B | −₩45B | −₩23B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩702B | ₩738B | ₩190B | ₩253B | ₩293B |
| Current assets | ₩521B | ₩550B | ₩135B | ₩192B | ₩229B |
| Cash and equivalents | ₩99B | ₩129B | ₩63B | ₩118B | ₩140B |
| Total liabilities | ₩161B | ₩122B | ₩41B | ₩33B | ₩34B |
| Current liabilities | ₩61B | ₩117B | ₩37B | ₩29B | ₩17B |
| Borrowings | ₩0 | ₩0 | ₩12B | ₩12B | ₩12B |
| Total equity | ₩541B | ₩616B | ₩148B | ₩220B | ₩259B |
| Shareholders' equity | ₩508B | ₩616B | ₩148B | ₩220B | ₩259B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩125B | ₩78B | −₩62B | −₩7.1B | −₩42B |
| Capital spending | ₩3B | ₩2.6B | ₩1.3B | ₩4.2B | ₩18B |
| Free cash flow | −₩128B | ₩76B | −₩64B | −₩11B | −₩60B |
Consolidated where available. Amounts in won.
Also known as: LigaChem Biosciences / 리가켐바이오 / 141080 / KRX:141080
Source: KRX statistical information